About this trial
Functional dyspepsia and gastroparesis are common stomach disorders with symptoms like early satiety, nausea, and abdominal pain, and are often evaluated with gastric emptying tests, although the correlation with symptoms is weak. Prokinetic agents (e.g., metoclopramide, erythromycin) and symptom modulators (e.g., nortriptyline, mirtazapine) are commonly used, but selecting the right medication can be difficult, as it's often based on symptoms rather than the underlying gastric issues. Body Surface Gastric Mapping (BSGM) using the Gastric Alimetry device is a novel, non-invasive tool to assess gastric myoelectrical activity and symptoms. This study aims to perform two BSGM recordings-one before and one after medical therapy-to understand how medications affect gastric function and identify baseline BSGM factors that could predict responses to treatment, potentially guiding tailored therapies based on individual gastric dysfunction.
Eligibility criteria
Qualifiers
Patients 18 years of age and older
Diagnosis of gastroparesis and/or functional dyspepsia
Being prescribed a prokinetic agent or symptom modulator for their clinical care
Able to undergo BSGM recording both before and during treatment
Disqualifiers
Under 18 years of age
Prior surgery on esophagus, stomach (appendectomy and cholecystectomy are allowed)
History of skin allergies or a history of extreme sensitivity to cosmetics or lotions
Pregnant women
Trial design
Treatments tested in this trial
- Gastric Alimetry
Treatment groups
Locations
3Sponsors and collaborators
University of Auckland, New Zealand
Lead sponsor
University of Western Sydney
Collaborator
Temple University
Collaborator
North Shore Hospital, New Zealand
Collaborator